Buclizine

This page contains recent news articles, when available, and an overview of Buclizine but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.


Overview:

Buclizine
(when available)

Pharmacology and use:
Buclizine is a piperazine-derivative antihistamine used as an antivertigo/antiemetic agent. Buclizine is used in the prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness. Additionally, it has been used in the management of vertigo in diseases affecting the vestibular apparatus. Although the mechanism by which buclizine exerts its antiemetic and antivertigo effects has not been fully elucidated, its central anticholinergic properties are partially responsible. The drug depresses labyrinth excitability and vestibular stimulation, and it may affect the medullary chemoreceptor trigger zone. It also possesses anticholinergic, antihistaminic, central nervous system depressant, and local anesthetic effects. For prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness and vertigo (dizziness caused by other medical problems).

Mechanism Of Action:
Vomiting (emesis) is essentially a protective mechanism for removing irritant or otherwise harmful substances from the upper GI tract. Emesis or vomiting is controlled by the vomiting centre in the medulla region of the brain, an important part of which is the chemotrigger zone (CTZ). The vomiting centre possesses neurons which are rich in muscarinic cholinergic and histamine containing synapses. These types of neurons are especially involved in transmission from the vestibular apparatus to the vomiting centre. Motion sickness principally involves overstimulation of these pathways due to various sensory stimuli. Hence the action of buclizine which acts to block the histamine receptors in the vomiting centre and thus reduce activity along these pathways. Furthermore since buclizine possesses anti-cholinergic properties as well, the muscarinic receptors are similarly blocked.

News Articles on Buclizine

Post-concussion syndrome healing process often a lengthy one  -  ‎Nov 13, 2009‎
He may benefit from trying an antivertigo/antinausea medication such as buclizine, cyclizine or meclizine. The blurred vision is more difficult. ... Tulsa World

Dr. Gott: Post-concussion syndrome explained  -  ‎Nov 10, 2009‎
He may benefit from trying an antivertigo/antinausea medication such as buclizine, cyclizine or meclizine. The blurred vision is more difficult. ... Pasadena Star-News

Brand Names/Synonyms:
Buclizine is also known by the following brand names and/or synonyms:
A 7668; AH 2526; Aphilan R; Aphilan-R Base; Bucladin; Bucladin-S; Buclifen; Buclina; Buclizina [Inn-Spanish]; Buclizine; Buclizine Dihydrochloride; Buclizine Hydrochloride; Buclizine, Hydrochloride; Buclizinum [Inn-Latin]; Buclodin; Histabuticine; Histabutizine; Histabutyzine; Histabutyzine Dihydrochloride; Histabutyzine Hydrochloride; Hitabutyzyne; Longifene; None; Posdel; Postafen; Softran; UCB 4445; UCB-4445; Vibazine; Vibazine Hydrochloride

Drug Category:
Buclizine is categorized under the following by the FDA: Antiemetics; Antihistamine; Anticholinergic; ATC:R06AE01

Dosage Forms:
TABLET (50 mg)

Absorption:
Rapidly absorbed following oral administration.

Interactions:
[an error occurred while processing this directive]



Chemical IUPAC Name:
1-[(4-chlorophenyl)-phenyl-methyl]-4-[(4-tert-butylphenyl)methyl]piperazine





Health Home | Conditions | Cancer | Medications | Surgery | Vaccines


The Cancer News Network


Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.



COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy